APPROVAL OF AUDITED FINANCIAL RESULTS AS ON 31.03.2026.
EPIGRAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Epigral Ltd reported FY2025-26 revenue of Rs 2,527.18 crore, marginally lower than Rs 2,550.13 crore in FY2024-25. Profit after tax declined to Rs 333.01 crore from Rs 356.70 crore in the prior year, a fall of about 6.6%, partly due to higher finance costs (up 35% to Rs 71.96 crore) and increased depreciation (up 27% to Rs 168.29 crore). The company switched to the lower tax regime under Section 115BAA, resulting in a one-time deferred tax credit of Rs 80.87 crore. Capital work-in-progress surged from Rs 63.89 crore to Rs 450.83 crore, indicating major expansion underway. Trade receivables nearly doubled from Rs 232 crore to Rs 416 crore. The Board recommended a final dividend of Rs 5 per share. Auditors issued an unmodified opinion on both standalone and consolidated results.
Revenue remained flat while profits declined due to higher interest and depreciation costs. The large increase in capital work-in-progress signals significant ongoing capex. Shareholders receive a dividend, but the stock may face pressure given the profit decline and rising debt levels.